Pharmacogenetics of immunosuppressants: Progress, pitfalls and promises

American Journal of Transplantation

Volumn 8, Issue 7, 2008, Pages 1374-1383

  Cattaneo, D ^a,b   Baldelli, S ^a,b   Perico, N ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b Center for Research on Organ Transplantation   (Italy)

Author keywords

Organ transplantation; Pharmacodynamics of immunosuppressants; Pharmacogenetics; Pharmacokinetics of immunosuppressive agents

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A5; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TARGETING; GENETIC POLYMORPHISM; GENOTYPE; HEART TRANSPLANTATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; ORGAN DONOR; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; CYTOCHROME P-450 CYP3A; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; ORGAN TRANSPLANTATION; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 47249151375     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02263.x     Document Type: Short Survey

References (54)

1. Cattaneo D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: A new approach to tailor immunosuppressive therapy. Am J Transplant 2004 4: 299 310.
2. Yagil Y, Yagil C. Pharmacogenomic considerations for immunosuppressive therapy. Pharmacogenomics 2003 4: 309 319.
3. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005 5: 207 217.
4. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: One step closer toward individualized immunosuppression? Pharmacogenomics 2005 6: 323 337.
5. Ng FL, Holt DW, MacPhee IA. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother 2007 8: 2045 2058.
6. Anglicheau D, Legendre C, Beaurne P, Thervet E. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update. Pharmacogenomics 2007 8: 835 849.
7. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007 82: 711 725.
8. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004 75: 13 33.
9. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000 97: 3473 3478.
10. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007 315: 525 528.
11. Barnard JB, Richardson S, Sheldon S et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation 2006 82: 1677 1682.
12. Anglicheau D, Le Corre D, Lechaton S et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005 5: 595 603.
13. Le Meur Y, Djebli N, Szelag JC et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006 80: 51 60.
14. Djebli N, Rousseau A, Hoizey G et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006 45: 1135 1148.
15. Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos 2008 29: 1 5.
16. Renders L, Frisman M, Ufer M et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007 81: 228 234.
17. Mourad M, Mourad G, Wallemacq P et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005 80: 977 984.
18. Remuzzi G, Lesti M, Gotti E et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial. Lancet 2004 364: 503 512.
19. Remuzzi G, Cravedi P, Costantini M et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: The MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007 18: 1973 1985.
20. McNeil, KShah S, Collett D et al. Long-term graft outcome with mycophenolate mofetil and azathioprine: A paired kidney analysis. Transplantation 2006 82: 1634 1639.
21. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002 3: 89 98.
22. Schütz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M. Azathioprine pharmacogenetics: The relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996 34: 199 205.
23. Formea CM, Myers-Huentelman H, Wu R et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. Am J Transplant 2004 4: 1810 1817.
24. Tassaneeyakul W, Srimarthpirom S, Reungjui S, Chansung K, Romphruk A, Tassaneeyakul W. Azathioprine-induced fatal myelosuppression in a renal-transplant recipient who carried heterozygous TPMT*1/*3C. Transplantation 2003 76: 265 266.
25. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: Lessons learned. Pharmacogenet Genomics 2006 16: 847 854.
26. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007 46: 13 58.
27. Girard H, Court MH, Bernard O et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004 14: 501 515.
28. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005 78: 351 361.
29. Djebli N, Picard N, Rèrolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genom 2007 17: 321 330.
30. Kagaya H, Inoue K, Miura M et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007 63: 279 288.
31. Baldelli S, Merlini S, Perico N et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007 8: 1127 1141.
32. Lévesque E, Delage R, Benoit-Biancamano MO et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007 81: 392 400.
33. Inoue K, Miura M, Satoh S et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 2007 29: 299 304.
34. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006 82: 1074 1084.
35. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): Its impact on drug disposition. Adv Drug Deliv Rev 2002 54: 1311 1331.
36. Miura M, Satoh S, Inoue K et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007 63: 1161 1169.
37. Gerber DJ, Hall D, Miyakawa T et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A 2003 100: 8993 8998.
38. Zhu D, Cardenas ME, Heitman J. Calcineurin mutants render T lymphocytes resistant to cyclosporin A. Mol Pharmacol 1996 50: 506 511.
39. Brogan IJ, Pravica V, Hutchinson IV. Genetic conservation of the immunophilin-binding domains of human calcineurin A1 and A2. Transpl Immunol 2000 8: 139 141.
40. Tang W, Arnett DK, Devereux RB et al. Identification of a novel 5-base pair deletion in calcineurin B (PPP3R1) promoter region and its association with left ventricular hypertrophy. Am Heart J 2005 150: 845 851.
41. Bowne SJ, Sullivan LS, Blanton SH et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Hum Mol Genet 2002 11: 559 568.
42. Wang J, Yang JW, Zeevi A et al. IMPDH1 Gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2007 Epub ahead of print
43. Wang J, Zeevi A, Webber S et al. A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007 17: 283 290.
44. Vannozzi F, Filipponi F, Di Paolo A et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc 2004 36: 2787 2790.
45. Yonezawa K, Tokunaga C, Oshiro N, Yoshino K. Raptor, a binding partner of target of rapamycin. Biochem Biophys Res Commun 2004 313: 437 441.
46. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003 2: 222 232.
47. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006 16: 119 127.
48. Wei-lin W, Jing J, Shu-sen Z et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006 12: 775 780.
49. Yu S, Wu L, Jin J et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006 81: 46 51.
50. Hauser IA, Schaeffeler E, Gauer S et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005 16: 1501 1511.
51. Goodsai F, Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006 7: 773 782.
52. Isler JA, Vesterqvist OE, Burczynski ME. Analytical validation of genotyping assays in the biomarker laboratory. Pharmacogenomics 2007 8: 353 368.
53. Burckart GJ, Liu XI. Pharmacogenetics in transplant patients: Can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 2006 28: 23 30.
54. Hamberg AK, Dahl ML, Barban M et al. A PK-PD model for predicting the impact of age, CYP2C9 and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 2007 81: 529 538.